Generics giant Teva turns to branded drugs R&D for its future
NEW YORK — A decade ago, Teva Pharmaceutical nearly sank its century-old business when it struck a $40.5 billion deal. In July 2015, Teva announced it would buy Allergan's generics business ...
NEW YORK — A decade ago, Teva Pharmaceutical nearly sank its century-old business when it struck a $40.5 billion deal.
In July 2015, Teva announced it would buy Allergan's generics business ...
